HIV vaccine trial shows promise in early safety testing

NCT ID NCT05781542

First seen Nov 14, 2025 · Last updated May 15, 2026 · Updated 27 times

Summary

This early-stage study tested a new DNA-based HIV vaccine in 46 healthy adults without HIV. The vaccine was designed to train the immune system to recognize and fight HIV. Researchers checked for side effects and measured immune responses. The goal was to see if the vaccine is safe and whether it triggers the desired immune reactions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Alabama CRS (Site ID: 31788)

    Birmingham, Alabama, 35294, United States

  • Bridge HIV CRS

    San Francisco, California, 94102, United States

  • Brigham and Women's Hospital Vaccine CRS [30007]

    Boston, Massachusetts, 02115, United States

  • CAPRISA eThekwini CRS

    Durban, KwaZulu-Natal, 4013, South Africa

  • Durban Adult HIV CRS

    Durban, KwaZulu-Natal, South Africa

  • Groote Schuur HIV CRS (Site ID: 31708)

    Cape Town, Western Cape, 7925, South Africa

  • San Francisco Vaccine and Prevention CRS

    San Francisco, California, 94102, United States

  • Soweto HVTN CRS

    Johannesburg, Gauteng, South Africa

Conditions

Explore the condition pages connected to this study.